Effects of native and cleaved forms of α1-antitrypsin on ME 1477 tumor cell functional activity

Cancer Detection and Prevention

Volumn 26, Issue 4, 2002, Pages 256-265

  Zelvyte, Inga ^a   Sjögren, Hans Olov ^b   Janciauskiene, Sabina ^a  

^a Malmö University Hospital   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

1 Antitrypsin; Metalloproteinases; Serpins; Tumor cells

Indexed keywords

ALPHA 1 ANTITRYPSIN; METALLOPROTEINASE; THYMIDINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; MALE; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY;

ALPHA 1-ANTITRYPSIN; ENZYME ACTIVATION; HUMANS; MALE; MELANOMA; METALLOENDOPEPTIDASES; MIDDLE AGED; THYMIDINE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR CELLS, CULTURED;

EID: 0036990970     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00090-9     Document Type: Article

References (43)

1. Mignatti P. Rifkin DB. Non-enzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. Adv Cancer Res 2000;78:103-57.
2. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7:14-23.
3. Farias E, Ranuncolo S, Cresta C, et al. Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer 2000;89:389-94.
4. Clawson GA. Protease inhibitors and carcinogenesis: a review. Cancer Invest 1996;14:597-608.
5. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Ann Rev Biochem 1983;52:655-709.
6. Ray MB, Geboes K, Callea F, et al. α1-Antitrypsin immunoreactivity in gastric carcinoid. Histopathology 1982;6:289-97.
7. Molmenti EP, Ziambaras T, Perlmutter DH. Evidence for an acute phase response in human intestinal epithelial cells. J Biol Chem 1993;268:14116-24.
8. Sawaya R, Zuccarello M. Highsmith R. α1-Antitrypsin in human brain tumors. J Neurosurg 1987;67:258-62.
9. Kawai M, Iida N, Inagaki S, Yamashita H, et al. Acute phase protein (α1-AAT) as a tumor marker in patients with ovarian cancer (OC). Gan No Rinsho 1989;35:799-803.
10. Keppler D, Markert M, Carnal B, et al. Human colon carcinoma cells synthesize and secrete α1-proteinase inhibitor. Biol Chem Hoppe Seyler 1996;377:301-11.
11. Allgayer H, Babic R, Grutzner K, et al. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 1998;16:62-73.
12. Tamir S, Kadner SS, Katz J, et al. Regulation of antitrypsin and antichymotrypsin synthesis by MCF-7 breast cancer cell sublines. Endocrinology 1990;127:1319-28.
13. Bergman D, Kadner SS, Cruz MR, et al. Synthesis of α1-antichymotrypsin and α1-antitrypsin by human trophoblast. Pediatr Res 1993;34:312-7.
14. Finlay TH, Tamir S, Kadner SS, et al. α1-Antitrypsin- and anchorage-independent growth of MCF-7 breast cancer cells. Endocrinology 1993;133:996-1002.
15. Yavelow J, Tuccillo A, Kadner SS, et al. α1-Antitrypsin blocks the release of transforming growth factor-alpha from MCF-7 human breast cancer cells. J Clin Endocrinol Metab 1997;82:745-52.
16. Kataoka H, Uchino H, Iwamura T, et al. Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of α1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am J Pathol 1999;154:457-68.
17. Janciauskiene S, Toth E, Sahlin S, et al. Immunochemical and functional properties of biliary α1-antitrypsin. Scand J Clin Lab Invest 1996;56:597-608.
18. Niemann MA, Baggott JE, Miller EJ. Binding of SPAAT, the 44-residue C-terminal peptide of α1-antitrypsin, to proteins of the extracellular matrix. Cell Biochem 1997;66:346-57.
19. Janciauskiene S, Lindgren S. Effects of fibrillar C-terminal fragment of cleaved α1-antitrypsin on cholesterol homeostasis in HepG2 cells. Hepatology 1999;29:434-42.
20. Zhi L, Xiaoye Z, Shapiro SD, et al. The serpin α1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000;102:647-55.
21. Sires UI, Murphy G, Baragi VM, et al. Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of α1-antitrypsin. Biochem Biophys Res Commun 1994;204:613-20.
22. Zhang Z, Winyard PG, Chidwick K, et al. Proteolysis of human native and oxidized α1-proteinase inhibitor by matrilysin and stromelysin. Biochim Biophys Acta 1994;1199:224-8.
23. Winyard PG, Zhang Z, Chidwick K, et al. Proteolytic inactivation of human α1-antitrypsin by human stromelysin. FEBS Lett 1991;279:91-4.
24. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurements with folin phenol reagents. J Biol Chem 1951;193:265-71.
25. Ausubel EM, Brent R, Kingston RE, et al. Short protocols in molecular biology. New York: Wiley; 1995.
26. Carrell RW, Stein PE. The biostructural pathology of the serpins: critical function of sheet opening mechanism. Biol Chem Hoppe Seyler 1996;377(1):1-17.
27. Hofmann UB, Westphal JR, van Muijen GNP, Ruiter DJ, et al. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000;115:337-44.
28. DeClerck YA, Perez N, Shimada H, et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701-8.
29. Sakata K, Shigemasa K, Nagai N, et al. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000;17:673-81.
30. Miyamoto Y, Akaike T, Maeda H. S-nitrosylated human α1-protease inhibitor. Biochim Biophys Acta 2000;1477:90-7.
31. She QB, Mukherjee JJ, Crilly KS, et al. α1-Antitrypsin can increase insulin-induced mitogenesis in various fibroblast and epithelial cell lines. FEBS Lett 2000;473:33-6.
32. Yao J, Baecher-Allan CM, Sharon J. Serpins identified as cell growth inhibitors in human plasma. Mol Cell Biol Res Commun 2000;3:76-81.
33. Janciauskiene S. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim Biophys Acta 2001;1535:221-35.
34. O'Reilly MS, Pirie-Shepherd S, Lane WS, et al. Anti-angiogenic activity of the cleaved conformation of the serpin atithrombin. Science 1999;285:1926-8.
35. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001;11:143-53.
36. Johansson N, Ahonen M, Kahari VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000;57:5-15.
37. Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ, et al. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 1990;87:3753-7.
38. Dabbagh K, Laurent GJ, Shock A, et al. α1-Antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signalling pathways. J Cell Physiol 2001:186:73-81.
39. Mast AE, Enghild JJ, Nagase H, et al. Kinetics and physiologic relevance of the inactivation of α1-proteinase inhibitor, α1-antichymotrypsin, and anti-thrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72 kDa gelatinase/type IV collagenase), and -3 (stromelysin). J Biol Chem 1991;266:15810-6.
40. Desrochers PE, Jefrfrey JJ, Weiss SJ. Interstitial collagenase (matrix metalloproteinase-1) express serpinase activity. J Clin Invest 1991;87:2258-65.
41. Michaelis J, Vissers MC, Winterbourn CC. Cleavage of α1-antitrypsin by human neutrophil collagenase. Matrix Suppl 1992;1:80-1.
42. Mallya SK, Hall JE, Lee HM, et al. Interaction of matrix metalloproteinases with serine protease inhibitors: new potential roles for matrix metalloproteinase inhibitors. Ann N Y Acad Sci 1994;732:303-14.
43. Karashima S, Kataoka H, Itoh H, et al. Prognostic significance of α1-antitrypsin in early stage of colorectal carcinomas. Int J Cancer 1990;45:244-50.